| MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Hana TOŠKOVÁ, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Gabriela VAŇKOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Zdeněk RÁČIL. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. Leukemia & Lymphoma. London: Informa Healthcare, Gordon and Breach, 2013, vol. 54, No 9, p. 2083-2087. ISSN 1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.762649. |
Other formats:
BibTeX
LaTeX
RIS
@article{1163539,
author = {Malčíková, Jitka and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Žáčková, Daniela and Tošková, Hana and Šebejová, Ludmila and Šmardová, Jana and Oltová, Alexandra and Vaňková, Gabriela and Juračková, Lenka and Trbušek, Martin and Pospíšilová, Šárka and Mayer, Jiří and Ráčil, Zdeněk},
article_location = {London},
article_number = {9},
doi = {http://dx.doi.org/10.3109/10428194.2012.762649},
keywords = {BCR-ABL1; T315I; chronic myelogenous leukemia; therapy},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & Lymphoma},
title = {The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.},
url = {http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal},
volume = {54},
year = {2013}
}
TY - JOUR
ID - 1163539
AU - Malčíková, Jitka - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Žáčková, Daniela - Tošková, Hana - Šebejová, Ludmila - Šmardová, Jana - Oltová, Alexandra - Vaňková, Gabriela - Juračková, Lenka - Trbušek, Martin - Pospíšilová, Šárka - Mayer, Jiří - Ráčil, Zdeněk
PY - 2013
TI - The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
JF - Leukemia & Lymphoma
VL - 54
IS - 9
SP - 2083-2087
EP - 2083-2087
PB - Informa Healthcare, Gordon and Breach
SN - 10428194
KW - BCR-ABL1
KW - T315I
KW - chronic myelogenous leukemia
KW - therapy
UR - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal
L2 - http://informahealthcare.com/doi/abs/10.3109/10428194.2012.762649?journalCode=lal
N2 - The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
ER -
MALČÍKOVÁ, Jitka, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ, Daniela ŽÁČKOVÁ, Hana TOŠKOVÁ, Ludmila ŠEBEJOVÁ, Jana ŠMARDOVÁ, Alexandra OLTOVÁ, Gabriela VAŇKOVÁ, Lenka JURAČKOVÁ, Martin TRBUŠEK, Šárka POSPÍŠILOVÁ, Jiří MAYER and Zdeněk RÁČIL. The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy. \textit{Leukemia \&{} Lymphoma}. London: Informa Healthcare, Gordon and Breach, 2013, vol.~54, No~9, p.~2083-2087. ISSN~1042-8194. Available from: https://dx.doi.org/10.3109/10428194.2012.762649.
|
